258 related articles for article (PubMed ID: 35354487)
21. Cannabis- and Substance-Related Epidemiological Patterns of Chromosomal Congenital Anomalies in Europe: Geospatiotemporal and Causal Inferential Study.
Reece AS; Hulse GK
Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141481
[TBL] [Abstract][Full Text] [Related]
22. Co-occurrence across time and space of drug- and cannabinoid- exposure and adverse mental health outcomes in the National Survey of Drug Use and Health: combined geotemporospatial and causal inference analysis.
Reece AS; Hulse GK
BMC Public Health; 2020 Nov; 20(1):1655. PubMed ID: 33148213
[TBL] [Abstract][Full Text] [Related]
23. Cannabis- and Substance-Related Carcinogenesis in Europe: A Lagged Causal Inferential Panel Regression Study.
Reece AS; Bennett K; Hulse GK
J Xenobiot; 2023 Jul; 13(3):323-385. PubMed ID: 37489337
[TBL] [Abstract][Full Text] [Related]
24. Geospatiotemporal and causal inference study of cannabis and other drugs as risk factors for female breast cancer USA 2003-2017.
Reece AS; Hulse GK
Environ Epigenet; 2022; 8(1):dvac006. PubMed ID: 35386387
[TBL] [Abstract][Full Text] [Related]
25. Geospatiotemporal and Causal Inferential Study of European Epidemiological Patterns of Cannabis- and Substance-Related Congenital Orofacial Anomalies.
Reece AS; Hulse GK
J Xenobiot; 2023 Feb; 13(1):42-74. PubMed ID: 36810431
[TBL] [Abstract][Full Text] [Related]
26. Epidemiological overview of multidimensional chromosomal and genome toxicity of cannabis exposure in congenital anomalies and cancer development.
Reece AS; Hulse GK
Sci Rep; 2021 Jul; 11(1):13892. PubMed ID: 34230557
[TBL] [Abstract][Full Text] [Related]
27. Letter to the editor on "Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017, parts 1-3".
Chen FY; Barnes M; Lewis EC
Arch Public Health; 2022 Jul; 80(1):172. PubMed ID: 35850921
[TBL] [Abstract][Full Text] [Related]
28. Clinical Epigenomic Explanation of the Epidemiology of Cannabinoid Genotoxicity Manifesting as Transgenerational Teratogenesis, Cancerogenesis and Aging Acceleration.
Reece AS; Hulse GK
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36834053
[TBL] [Abstract][Full Text] [Related]
29. European epidemiological patterns of cannabis- and substance-related congenital cardiovascular anomalies: geospatiotemporal and causal inferential study.
Reece AS; Hulse GK
Environ Epigenet; 2022; 8(1):dvac015. PubMed ID: 35966825
[TBL] [Abstract][Full Text] [Related]
30. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15.
Niesink RJ; Rigter S; Koeter MW; Brunt TM
Addiction; 2015 Dec; 110(12):1941-50. PubMed ID: 26234170
[TBL] [Abstract][Full Text] [Related]
31. Chromothripsis and epigenomics complete causality criteria for cannabis- and addiction-connected carcinogenicity, congenital toxicity and heritable genotoxicity.
Reece AS; Hulse GK
Mutat Res; 2016 Jul; 789():15-25. PubMed ID: 27208973
[TBL] [Abstract][Full Text] [Related]
32. Quantitation of Δ8-THC, Δ9-THC, Cannabidiol and 10 Other Cannabinoids and Metabolites in Oral Fluid by HPLC-MS-MS.
Lin L; Amaratunga P; Reed J; Huang P; Lemberg BL; Lemberg D
J Anal Toxicol; 2022 Feb; 46(1):76-88. PubMed ID: 33270860
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.
Ligresti A; Moriello AS; Starowicz K; Matias I; Pisanti S; De Petrocellis L; Laezza C; Portella G; Bifulco M; Di Marzo V
J Pharmacol Exp Ther; 2006 Sep; 318(3):1375-87. PubMed ID: 16728591
[TBL] [Abstract][Full Text] [Related]
34. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.
Miller OS; Elder EJ; Jones KJ; Gidal BE
Epilepsy Behav; 2022 Feb; 127():108514. PubMed ID: 34998268
[TBL] [Abstract][Full Text] [Related]
35. Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users.
Huestis MA; Sempio C; Newmeyer MN; Andersson M; Barnes AJ; Abulseoud OA; Blount BC; Schroeder J; Smith ML
J Anal Toxicol; 2020 Oct; 44(7):651-660. PubMed ID: 32369162
[TBL] [Abstract][Full Text] [Related]
36. A pharmacological characterization of Cannabis sativa chemovar extracts.
Devsi A; Kiyota B; Ouellette T; Hegle AP; Rivera-Acevedo RE; Wong J; Dong Y; Pugsley MK; Fung T
J Cannabis Res; 2020 May; 2(1):17. PubMed ID: 33526117
[TBL] [Abstract][Full Text] [Related]
37. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile.
Swift W; Wong A; Li KM; Arnold JC; McGregor IS
PLoS One; 2013; 8(7):e70052. PubMed ID: 23894589
[TBL] [Abstract][Full Text] [Related]
38. A new Cannabis genome assembly associates elevated cannabidiol (CBD) with hemp introgressed into marijuana.
Grassa CJ; Weiblen GD; Wenger JP; Dabney C; Poplawski SG; Timothy Motley S; Michael TP; Schwartz CJ
New Phytol; 2021 May; 230(4):1665-1679. PubMed ID: 33521943
[TBL] [Abstract][Full Text] [Related]
39. Cannabis constituents reduce seizure behavior in chemically-induced and scn1a-mutant zebrafish.
Thornton C; Dickson KE; Carty DR; Ashpole NM; Willett KL
Epilepsy Behav; 2020 Sep; 110():107152. PubMed ID: 32585475
[TBL] [Abstract][Full Text] [Related]
40. Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
Lee D; Karschner EL; Milman G; Barnes AJ; Goodwin RS; Huestis MA
Drug Alcohol Depend; 2013 Jun; 130(1-3):68-76. PubMed ID: 23146820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
